Skip to main content

Tevogen Inc.

corporate_fare Company Profile

Tevogen Inc.

TVGN·NASDAQ·Life Sciences·CIK 0001860871

We are a clinical-stage specialty immunotherapy company that develops off-the-shelf, precision T cell therapies. Our therapies use CD8+ cytotoxic T lymphocytes (CTLs), also known as killer T cells, which are white blood cells that destroy infected, malignant, or damaged cells. These therapies are designed to treat infectious diseases, cancers, and other disorders. Our precision T cell technology, ExacTcell, is a set of processes and methodologies used to develop, enrich, and expand single human leukocyte antigen (HLA) restricted CTL therapies with proactively selected, precisely defined targets. HLA molecules are proteins important for the immune system to distinguish between "self" and "foreign" cells, and HLA types vary among individuals. ExacTcell therapies are based on carefully selected, naturally occurring CTLs that recognize targets from the body's native T cell receptor pool, differing from genetically engineered T cell therapies. The CD8+ CTLs in ExacTcell-based products target multiple and distinct antigens. These allogeneic therapeutics are pre-manufactured, ready-to-use, and intended for infusion into individuals other than the original donor.

Tevogen Inc. (NASDAQ:TVGN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 32 items for TVGN at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Tevogen Bio Regains Nasdaq Compliance, Removing Delisting Risk
  • Tevogen.AI's PredicTcell™ Beta Shows Improved Precision, Expanding Drug Discovery Capabilities
  • Tevogen Bio's Long COVID Therapy Shows 100% Efficacy in PoC Data, Expands Patient Eligibility to 65% US Population
  • Tevogen Bio Signs LOI to Evaluate Apozeal Pharmaceutical Acquisition, Advancing Generics Strategy
  • Tevogen Bio Finalizes 1-for-50 Reverse Stock Split to Regain Nasdaq Compliance, Creates Significant Dilution Headroom

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$26.28M
Diluted EPS
-$8.08
Op. Cash Flow
-$12.33M
Free Cash Flow
-$12.39M
Operating Income
-$26.14M
Cash & Equivalents
$0
Debt / Equity
0.00×
Shares Outstanding
4.02M sh
Source: 10-K · filed 2026-04-30 · accession 0001493152-26-020704
$5.9
52-week range · as of 2026-11-17 $3.64 – $24.91
Market cap
$405.2M
Volume
9.4K (1.1× avg)
3-mo avg 8.9K
Live data · 2026-11-22 12:52 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed TVGN - Filings & News (Page 2)

TVGN
Mar 25, 2026, 2:20 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.23
Real-time Price: $5.90 info
Change: +$0.670 (+13%) info
Market Cap: $405.205M info
TVGN
Mar 13, 2026, 12:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $7.04
Real-time Price: $5.90 info
Change: -$1.14 (-16%) info
Market Cap: $405.205M info
TVGN
Mar 11, 2026, 3:15 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $7.30
Real-time Price: $5.90 info
Change: -$1.40 (-19%) info
Market Cap: $405.205M info
TVGN
Mar 05, 2026, 2:50 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $0.156697
Real-time Price: $5.90 info
Change: Reverse Stock Split info
Market Cap: $405.205M info
TVGN
Mar 04, 2026, 9:04 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.1892
Real-time Price: $5.90 info
Change: Reverse Stock Split info
Market Cap: $405.205M info
TVGN
Mar 04, 2026, 8:01 AM EST
Source: Reuters
Importance Score:
9
Price at Filing: $0.1905
Real-time Price: $5.90 info
Change: Reverse Stock Split info
Market Cap: $405.205M info
TVGN
Feb 27, 2026, 2:20 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $0.2694
Real-time Price: $5.90 info
Change: Reverse Stock Split info
Market Cap: $405.205M info
TVGN
Feb 26, 2026, 9:36 AM EST
Filing Type: 424B3
Importance Score:
9
Price at Filing: $0.293
Real-time Price: $5.90 info
Change: Reverse Stock Split info
Market Cap: $405.205M info
TVGN
Feb 25, 2026, 5:00 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.290
Real-time Price: $5.90 info
Change: Reverse Stock Split info
Market Cap: $405.205M info
TVGN
Jan 30, 2026, 3:37 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.315
Real-time Price: $5.90 info
Change: Reverse Stock Split info
Market Cap: $405.205M info
TVGN
Jan 26, 2026, 5:29 PM EST
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $0.3304
Real-time Price: $5.90 info
Change: Reverse Stock Split info
Market Cap: $405.205M info
TVGN
Jan 16, 2026, 5:29 PM EST
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $0.3355
Real-time Price: $5.90 info
Change: Reverse Stock Split info
Market Cap: $405.205M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets